Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Intellia received a consensus recommendation of Hold from 20 brokerages (2 sell, 8 hold, 9 buy, 1 strong buy), with an average 12‑month price target of $19.59.
• In its latest quarter Intellia reported EPS of ($0.83) beating estimates of ($0.99) and revenue of $23.02M (vs. $12.17M expected), but the company remains unprofitable and analysts forecast -5.07 EPS for the year.
• Insiders sold 53,051 shares (~$488,600) last quarter — including EVP sales on Jan. 5 — leaving insiders with 3.10% ownership while institutional investors own 88.77% of the stock.

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has earned a consensus recommendation of "Hold" from the twenty brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $19.5909.

A number of brokerages have weighed in on NTLA. Citizens Jmp boosted their target price on shares of Intellia Therapeutics from $21.00 to $28.00 and gave the company a "market outperform" rating in a research note on Tuesday, March 3rd. KeyCorp set a $25.00 price target on Intellia Therapeutics in a research note on Wednesday, January 28th. Leerink Partners lifted their price objective on Intellia Therapeutics from $27.00 to $29.00 and gave the stock an "outperform" rating in a report on Tuesday, March 3rd. Chardan Capital reiterated a "buy" rating and set a $26.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 27th. Finally, Robert W. Baird set a $7.00 target price on Intellia Therapeutics in a report on Tuesday, January 27th.

Insider Activity

In related news, EVP Birgit C. Schultes sold 8,508 shares of the business's stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the sale, the executive vice president directly owned 98,533 shares in the company, valued at approximately $907,488.93. The trade was a 7.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP James Basta sold 10,397 shares of the company's stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $95,756.37. Following the sale, the executive vice president directly owned 101,528 shares of the company's stock, valued at approximately $935,072.88. This represents a 9.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 53,051 shares of company stock valued at $488,600 in the last quarter. 3.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of NTLA. Schroder Investment Management Group lifted its holdings in Intellia Therapeutics by 1,593.4% during the second quarter. Schroder Investment Management Group now owns 406,425 shares of the company's stock valued at $3,812,000 after purchasing an additional 382,425 shares in the last quarter. Farallon Capital Management LLC bought a new position in shares of Intellia Therapeutics in the third quarter worth approximately $10,486,000. Marex Group plc purchased a new stake in shares of Intellia Therapeutics in the second quarter worth $5,849,000. JPMorgan Chase & Co. increased its stake in shares of Intellia Therapeutics by 73.0% in the second quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company's stock worth $8,822,000 after purchasing an additional 396,858 shares in the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Intellia Therapeutics by 239.7% during the 3rd quarter. SG Americas Securities LLC now owns 131,070 shares of the company's stock valued at $2,264,000 after purchasing an additional 92,485 shares during the period. Hedge funds and other institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Stock Down 5.8%

Shares of NTLA stock opened at $11.65 on Tuesday. The company has a 50 day moving average price of $13.14 and a 200-day moving average price of $13.35. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.25. The firm has a market capitalization of $1.38 billion, a PE ratio of -3.04 and a beta of 2.09.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, beating analysts' consensus estimates of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The company had revenue of $23.02 million for the quarter, compared to the consensus estimate of $12.17 million. During the same quarter in the prior year, the firm earned ($1.27) earnings per share. The firm's revenue for the quarter was up 78.4% compared to the same quarter last year. Analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc NASDAQ: NTLA is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.